Zobrazeno 1 - 10
of 49
pro vyhledávání: ''
Autor:
Yucai Wang, Arushi Khurana, Thomas M. Habermann, Jose C. Villasboas, Brian K. Link, William R. Macon, Stephen M. Ansell, Matthew J. Maurer, Raphael Mwangi, James R. Cerhan, Rebecca L. King, Christopher Strouse, Grzegorz S. Nowakowski, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed it
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-8 (2021)
Blood Cancer Journal
Blood Cancer Journal
We conducted a prospective cohort study in newly diagnosed systemic light chain (AL) amyloidosis patients (N = 59) to study patient-reported outcomes (PROs) through the first year. The median age was 68 years with 42% female, 8% Black, and 78% lambda
Autor:
Luke Zheng, Vaishali Sanchorawala, Dina Brauneis, J. Mark Sloan, Shayna Sarosiek, Karen Quillen
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 8, Pp 1-6 (2020)
Blood Cancer Journal
Blood Cancer Journal
Hematologic complete response (hemCR) in AL amyloidosis requires absence of monoclonal protein by immunofixation electrophoreses (IFE) and normal serum free light chain ratio (FLCR). Recent literature suggests that an involved free light chain (iFLC)
Autor:
Maria Gavriatopoulou, Lia-Angela Moulopoulos, Evangelos Terpos, Nikolaos Kanellias, Andriani Βoultadaki, Efstathios Kastritis, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Charis Bourgioti, Despina Fotiou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Vassilis Koutoulidis
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 9, Pp 1-7 (2020)
Blood Cancer Journal
Blood Cancer Journal
Introduction: Multiple myeloma (MM) is the second most common haematological malignancy and is characterized by bone marrow infiltration of monoclonal plasma cells and end-organ involvement. Smoldering MM (SMM) is an intermediate clinical entity betw
Autor:
Angela Dispenzieri, David Dingli, Betsy LaPlant, Yi Lin, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, Miriam Hobbs, Amie Fonder, Morie A. Gertz, Eli Muchtar, S. Vincent Rajkumar, Nelson Leung, Rahma Warsame, Taxiarchis Kourelis, Shaji Kumar, Martha Q. Lacy, Ronald S. Go, Suzanne R. Hayman, Kristina Laumann, Robert A. Kyle, Wilson I. Gonsalves, Gabriela Perez Burbano, Prashant Kapoor, Francis K. Buadi, Yi L. Hwa
Publikováno v:
Blood Cancer Journal, Vol 10, Iss 1, Pp 1-9 (2020)
Blood Cancer Journal
Blood Cancer Journal
Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and assess new response/progression criteria. Studies included were lenalido
Autor:
Feng Wang, Naveen Pemmaraju, Li Zhao, Maliha Khan, Tianyu Cai, Hannah C. Beird, Marina Konopleva, Mansour Alfayez, P. Andrew Futreal, Joseph D. Khoury
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-9 (2019)
Blood Cancer Journal
Blood Cancer Journal
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, male-predominant hematologic malignancy with poor outcomes and with just one recently approved agent (tagraxofusp). It is characterized by the abnormal proliferation of precursor plasmac
Autor:
Madhav V. Dhodapkar, Jonathan L. Kaufman, Vikas Gupta, Sagar Lonial, Ajay K. Nooka, Zhengjia Chen, Jiayi Wu, David L. Jaye, Leonard T. Heffner, Craig C. Hofmeister, Subir Goyal, Nisha Joseph, Lawrence H. Boise, Timothy M. Schmidt, Benjamin G. Barwick, Leon Bernal
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 12, Pp 1-13 (2019)
Blood Cancer Journal
Blood Cancer Journal
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively a
Autor:
F. Hitz, M. Kraus, T. Pabst, D. Hess, L. Besse, T. Silzle, U. Novak, K. Seipel, S. Rondeau, S. Stüdeli, S. Berardi Vilei, P. Samaras, U. Mey, C. Driessen, for the Swiss Group for Clinical Cancer Research SAKK
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 9, Pp 1-8 (2019)
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Blood Cancer Journal
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Blood Cancer Journal
The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenalidomide-r
Autor:
Brandt Jones, Nicola J. Camp, Michael H. Tomasson, Ethan Davis, Karen Curtin, Michael J. Madsen, Cassandra Garner, Justin A. Williams, Martha Glenn
Publikováno v:
Blood Cancer Journal, Vol 9, Iss 3, Pp 1-9 (2019)
Blood Cancer Journal
Blood Cancer Journal
Abnormal serum immunoglobulin (Ig) free light chains (FLC) are established biomarkers of early disease in multiple B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL). Heavy chains have also been shown to be biomarkers in plasm
Autor:
Irbaz Bin Riaz, Morie A. Gertz, Shaji Kumar, M. Hasib Sidiqi, Wilson I. Gonsalves, Martha Q. Lacy, Eli Muchtar, S. Vincent Rajkumar, Angela Dispenzieri, Rahma Warsame, Nelson Leung, Francis K. Buadi, William J. Hogan, Prashant Kapoor, Taxiarchis Kourelis, David Dingli, Mohammed A. Aljama
Publikováno v:
Blood Cancer Journal, Vol 8, Iss 11, Pp 1-8 (2018)
Blood Cancer Journal
Blood Cancer Journal
We retrospectively reviewed all patients (n = 243) receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction followed by autologous stem cell transplantation (ASCT) for multiple myeloma at the Mayo Clinic between January 2010 and April of